Skip to main content

Detail

Johannes Längle
Dr.med.univ. Johannes Längle, PhD

Department of Surgery (Division of General Surgery)
Position: Doctor-in-training

ORCID: 0000-0003-4771-1398
T +43 1 40400 73525, 56210
johannes.laengle@meduniwien.ac.at

Further Information

Keywords

Apoptosis; Cell Death; Chemoradiotherapy; Clinical Immunology; Colorectal Neoplasms; Colorectal Surgery; Cytotoxicity, Immunologic; DNA Damage; General Surgery; Liver Neoplasms; Macrophages; Monocytes; Natural Killer T-Cells; Necrosis; Oncolytic Virotherapy; Oncolytic Viruses; Phagocytosis; Radiotherapy; T Cells; Translational Medical Research

Research interests

My main research is focused on:

  • Tumor immunology
  • Immuno-oncology
  • Immunogenic cell death

In particular I am investigating the role of therapy-induced (i.e. chemotherapy, radiotherapy) biological changes in the tumor-immune microenvironment (TIME) of human solid malignancies, such as colorectal cancer (CRC) or colorectal liver metastases (CLM), in a human-translational setting. The research aims are to examine the induction and consequences of a therapy-induced endoplasmic reticulum (ER) stress response, immunogenic cell death (ICD), type I and type II interferon (IFN) induction and tumor-infiltrating immune cells with clinical outcome. My ultimate goal is to develop novel concepts of cancer immunotherapy, using a rational combined treatment approach.

Techniques, methods & infrastructure

  • Cell culture techniques (i.e. antibody-dependent cell-mediated cytotoxicity & phagocytosis assay)
  • Molecular biology techniques (i.e. FCM, IFC, IHC, IF, ICC, RT-qPCR, ELISA, WB)
  • Whole-slide imaging and quantification

Our Surgical Research Laboratories are endowed with various instruments for standard techniques in molecular biology, cell culture, protein biochemistry and immunology. They are located within the Anna Spiegel Research Building, also known as the „Center of Translational Research“ of the Medical University of Vienna, which is equiped with Core Facilities for Genomics, Proteomics, Flow Cytometry and Imaging, providing scientists easy access to state-of-the-art high-end equipment and cutting edge technology to address highly sophisticated research questions.

Furthermore, our studies are arried out within the frames of the Comprehensive Cancer Center (CCC) Vienna and the Ludwig Boltzmann Institute Applied Diagnostics (lbi:ad).

Selected publications

  1. Laengle, J. et al., 2020. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis. Journal for ImmunoTherapy of Cancer, 8(1), p.e000195. Available at: http://dx.doi.org/10.1136/jitc-2019-000195.
  2. Laengle, J. et al., 2018. DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells. Theranostics, 8(12), pp.3198–3213. Available at: http://dx.doi.org/10.7150/thno.24699.
  3. Hock, K. et al., 2017. Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo. Surgery, 161(3), pp.735–746. Available at: http://dx.doi.org/10.1016/j.surg.2016.08.045.
  4. Weiss, R. et al., 2015. Interleukin-24 inhibits influenza A virus replication in vitro through induction of toll-like receptor 3 dependent apoptosis. Antiviral Research, 123, pp.93–104. Available at: http://dx.doi.org/10.1016/j.antiviral.2015.09.005.
  5. Petricevic, B. et al., 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. Journal of Translational Medicine, 11(1), p.307. Available at: http://dx.doi.org/10.1186/1479-5876-11-307.